Development of local application of a FAK inhibitor for the hybrid treatment of aortic aneurysm

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K17718
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55030:Cardiovascular surgery-related
• Research Institution: Yamaguchi University
• Principal Investigator: Harada Takasuke 山口大学, 医学部附属病院, 助教 (60650322)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 大動脈瘤 / 薬物療法 / 徐放性製剤

Outline of Final Research Achievements

The aim of this study was to develop PLGA nanoparticles containing a FAK inhibitor in order for the hybrid treatment of aortic aneurysm to be realized. The biodegradable PLGA nanoparticles containing FAK inhibitor PF573228 were prepared and their sustained effects of blocking FAK activity were observed in cultured macrophages. Our data suggest a possibility that inflammation in aneurysms may be controlled by a novel hybrid treatment of aortic aneurysm.

Free Research Field

外科学　心臓血管外科学

Academic Significance and Societal Importance of the Research Achievements

本研究は、外科的治療のみでは制御困難な大動脈瘤に対して、世界初の外科的治療と薬物治療とのハイブリッド治療法の開発をめざすトランスレーショナルリサーチである。特にFAKは研究代表者が自ら発見した有望な分子標的であり、FAK阻害剤の徐放性製剤を用いる薬物療法と日常の血管外科診療で行っているステントグラフト内挿術手技とのハイブリッド治療システムが実臨床に応用されれば、大動脈瘤患者の予後とQOLの大幅な向上に繋がることが期待できる。